AbCellera Biologics
- Country
- Ownership
- -
- Employees
- 586
- Market Cap
- -
- Introduction
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
- Conditions
- Vasomotor Symptoms Associated With MenopauseHealthy Volunteers
- Interventions
- Biological: Placebo
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- AbCellera Biologics Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT07118891
- Locations
- 🇨🇦
Altasciences Company Inc., Mount-Royal, Quebec, Canada
A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Biological: Placebo (Normal Saline 0.9%)
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- AbCellera Biologics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT07108894
- Locations
- 🇨🇦
Altasciences Company Inc., Mont-Royal, Quebec, Canada
News
AbCellera Advances Two First-in-Class Antibody Therapies to Phase 1 Trials Following Strategic Pivot
AbCellera Biologics has received Health Canada authorization to begin Phase 1 trials for ABCL635, a first-in-class NK3R antagonist targeting menopause-related hot flashes, and ABCL575, an OX40L-targeting antibody for atopic dermatitis, both scheduled to start in Q3 2025.